Actively Recruiting
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-04-08
75
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
CONDITIONS
Official Title
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and able to communicate and follow study requirements
- Age between 18 and 75 years, male or female
- Have atopic dermatitis at screening
You will not qualify if you...
- Allergic to the study drug or its ingredients
- Have other active skin diseases or skin problems affecting evaluation
- Have or have had cancer
- Have serious medical conditions deemed unsuitable by the investigator
- Are pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510091
Actively Recruiting
Research Team
R
Ran Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here